Eriodictyol protects against diabetic retinopathy (Kong et al. 2021) and significantly lowers retinal TNFα, intercellular adhesion molecule 1, vascular endothelial growth factor (VEGF), and endothelial nitric oxide synthase. Here, VEGFA is linked to diabetic retinopathy.